scholarly journals Canadian Consensus Guidelines for the Optimal Use of Maraviroc in the Treatment of HIV-Infected Adults

2010 ◽  
Vol 21 (4) ◽  
pp. 159-172 ◽  
Author(s):  
Anita Rachlis ◽  
Marianne Harris ◽  
Richard Lalonde ◽  
Stephen D Shafran ◽  
Cécile Tremblay ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Providers ◽  
Hiv Treatment ◽  
Care Providers ◽  
Expert Opinions ◽  
Hiv Management ◽  
Conference Presentations ◽  
Canadian Health ◽  
Canadian Health Care ◽  
Group Members

BACKGROUND AND OBJECTIVES: A Canadian group, consisting of six physicians and an HIV researcher with significant experience and knowledge in HIV management, reviewed the available data and developed guidelines for Canadian health care providers (who treat HIV infection) on the appropriate use of maraviroc (UK-427,857) in HIV-infected adults.METHODS: Evidence from the published literature and conference presentations, as well as the expert opinions of the group members were considered and evaluated to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, as well as from four other physicians across Canada with expertise in HIV treatment and experience with the use of maraviroc. The final recommendations represent the core group’s consensus agreement once all feedback was considered.RESULTS/CONCLUSIONS: Recommendations were developed to guide physicians and other health care providers in the optimal use of maraviroc. The recommendations were considered in light of the fact that the decision to include maraviroc in an antiretroviral regimen depends not only on issues that concern all antiretroviral agents, such as efficacy, safety, resistance and drug interactions, but also on the issue of viral tropism, which is unique to maraviroc and other CCR5 inhibitors.

Intrauterine Contraception: Knowledge and Prescribing Practices of Canadian Health Care Providers

2019 ◽  
Vol 41 (8) ◽  
pp. 1084-1092 ◽  
Author(s):  
Jocelynn Cook ◽  
Ashley Waddington ◽  
Denise Black ◽  
Dustin Costescu ◽  
Danica Desjardins ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Providers ◽  
Care Providers ◽  
Prescribing Practices ◽  
Intrauterine Contraception ◽  
Canadian Health ◽  
Canadian Health Care

scholarly journals Canadian recommendations for the management of breakthrough cancer pain

2016 ◽  
Vol 23 (2) ◽  
pp. 96 ◽  
Author(s):  
P. Daeninck ◽  
B. Gagnon ◽  
R. Gallagher ◽  
J.D. Henderson ◽  
Y. Shir ◽  
...  
Keyword(s):  
Health Care ◽  
Cancer Pain ◽  
Health Care Providers ◽  
Immediate Release ◽  
Care Providers ◽  
Onset Of Action ◽  
Breakthrough Cancer Pain ◽  
Appropriate Treatment ◽  
Canadian Health ◽  
Canadian Health Care

Breakthrough cancer pain (btcp) represents an important element in the spectrum of cancer pain management. Because most btcp episodes peak in intensity within a few minutes, speed of medication onset is crucial for proper control. In Canada, several current provincial guidelines for the management of cancer pain include a brief discussion about the treatment of btcp; however, there are no uniform national recommendations for the management of btcp. That lack, accompanied by unequal access to pain medication across the country, contributes to both regional and provincial variability in the management of btcp.Currently, immediate-release oral opioids are the treatment of choice for btcp. This approach might not always offer optimal speed for onset of action and duration to match the rapid nature of an episode of btcp. Novel transmucosal fentanyl formulations might be more appropriate for some types of btcp, but limited access to such drugs hinders their use. In addition, the recognition of btcp and its proper assessment, which are crucial steps toward appropriate treatment selection, remain challenging for many health care professionals.To facilitate appropriate management of btcp, a group of prominent Canadian specialists in palliative care, oncology, and anesthesiology convened to develop a set of recommendations and suggestions to assist Canadian health care providers in the treatment of btcp and the alleviation of the suffering and discomfort experienced by adult cancer patients.

scholarly journals Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV-Infected Adults – Canadian Consensus Guidelines

2009 ◽  
Vol 20 (3) ◽  
pp. e67-e80 ◽  
Author(s):  
Anita Rachlis ◽  
Jonathan B Angel ◽  
Marianne Harris ◽  
Stephen D Shafran ◽  
Rachel Therrien ◽  
...  
Keyword(s):  
Hiv Treatment ◽  
Consensus Guidelines ◽  
Antiretroviral Drug Resistance ◽  
Expert Opinions ◽  
Viral Load Reduction ◽  
Hiv Management ◽  
Antiretroviral Drug ◽  
Conference Presentations ◽  
Group Members ◽  
Canadian Group

BACKGROUND AND OBJECTIVES: A meeting of a Canadian group with significant experience and knowledge in HIV management, consisting of five physicians, a pharmacist and an AIDS researcher, was convened. Their goal was to develop guidance for Canadian HIV-treating physicians on the appropriate use of raltegravir (MK-0518, Isentress®, Merck Frosst Canada Inc) in HIV-infected adults.METHODS: Evidence from the published literature and conference presentations, as well as expert opinions of the group members, was considered and evaluated to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, as well as from five other physicians and scientists across Canada with expertise in HIV treatment and antiretroviral drug resistance, and experience in the use of raltegravir. The final recommendations represent the core group’s consensus agreement once all feedback was considered.RESULTS/CONCLUSIONS: Recommendations were developed to guide physicians in the optimal use of raltegravir. The issues considered included raltegravir’s role in overall treatment strategy, efficacy, durability of effect, rate of viral load reduction, resistance, safety/toxicity, pharmacokinetics and drug interactions.

scholarly journals Canadian Consensus Guidelines for the Optimal Use of Etravirine in the Treatment of HIV-Infected Adults

2009 ◽  
Vol 20 (2) ◽  
pp. e24-e34 ◽  
Author(s):  
Marianne Harris ◽  
Jonathan B Angel ◽  
Jean-Guy Baril ◽  
Anita Rachlis ◽  
Benoit Trottier
Keyword(s):  
Antiretroviral Treatment ◽  
Disease Status ◽  
Hiv Treatment ◽  
Hiv Disease ◽  
Consensus Guidelines ◽  
Expert Opinions ◽  
Hiv Management ◽  
Predictors Of Response ◽  
Conference Presentations ◽  
Group Members

BACKGROUND AND OBJECTIVES: A group of five Canadian physicians with significant experience in HIV management was convened. Their goal was to develop guidance specifically for Canadian HIV-treating physicians on the appropriate use of etravirine (TMC125, Intelence, Tibotec BVBA, Belgium) in adult HIV-infected patients.METHODS: Evidence from the published literature, conference presentations and expert opinions of the group members were used to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, and from seven other physicians across Canada with clinical HIV treatment expertise and experience in the use of etravirine, as well as two Canadian scientists with HIV expertise. The final recommendations represent the core group’s consensus agreement, taking all feedback into consideration.RESULTS AND CONCLUSIONS: The recommendations were developed to guide physicians in the optimal use of etravirine. The issues considered included HIV disease status, antiretroviral treatment history, drug resistance profiles, predictors of response to etravirine, background antiretroviral regimen and drug-drug interactions.

Sign in / Sign up

Export Citation Format

Share Document